Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Open Access Gateway

GLP-1 and Ghrelin Attenuate High Glucose/High Lipid-Induced Apoptosis and Senescence of Human Microvascular Endothelial Cells

Liao P. · Yang D. · Liu D. · Zheng Y.

Author affiliations

Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Corresponding Author

Yuehong Zheng

Department of Vascular Surgery,

Peking Union Medical College Hospital,

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, (China)

Fax +86 10 69152502, E-Mail yuehongzheng@yahoo.com

Related Articles for ""

Cell Physiol Biochem 2017;44:1842–1855

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Abstract

Background/Aims: GLP-1 and ghrelin are common appetite-regulating hormones. Both have multiple functions beyond metabolic regulation. However, the effects of GLP-1 and ghrelin on endothelial biology are not fully understood. Here, we investigate the roles of GLP-1 and ghrelin in microvascular endothelial apoptosis and senescence. Methods: Human microvascular endothelial cells (HMECs) were exposed to high glucose/high lipid (HG/HL) conditions and treated with GLP-1 or ghrelin. Cellular apoptosis, senescence, and mitochondrial function were measured. In addition, the MAPK and Akt signaling pathways were examined. Results: Both GLP-1 and ghrelin treatment decreased the number of TUNEL-positive cells and inhibited caspase-3 and PARP cleavage and mitochondrial dysfunction in HG/HL-exposed HMECs. GLP-1, but not ghrelin decreased the number of β-galactosidase (β-gal)-positive cells. Furthermore, GLP-1 and ghrelin inhibited ERK1/2, JNK1/2, and p38 signaling. GLP-1 suppressed Akt signaling, but ghrelin had no effect. Moreover, JNK1/2 and p38 inhibitors, but not ERK1/2 and Akt inhibitors, decreased the number of TUNEL-positive cells. Additionally, only the Akt inhibitor decreased the number of β-gal-positive cells. Conclusion: These results demonstrate that GLP-1 and ghrelin inhibit mitochondrial dysfunction under HG/HL conditions, and suppress endothelial apoptosis via inhibiting JNK1/2 and p38 signaling; moreover, GLP-1 alleviates endothelial senescence via inactivating Akt signaling.

© 2017 The Author(s). Published by S. Karger AG, Basel


References

  1. Patel VJ, Joharapurkar AA, Shah GB, Jain MR: Effect of GLP-1 based therapies on diabetic dyslipidemia. Curr Diabetes Rev 2014; 10: 238-250.
  2. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286.
  3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
  4. Liu H, Hu Y, Simpson RW, Dear AE: Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J Endocrinol 2008; 196: 57-65.
  5. Aronis KN, Chamberland JP, Mantzoros CS: GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 2013; 62: 1279-1286.
  6. Mao Y, Tokudome T, Kishimoto I: Ghrelin as a treatment for cardiovascular diseases. Hypertension 2014; 64: 450-454.
  7. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A: Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-1037.
  8. Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, Kangawa K, Kohno N, Yoshizumi M: Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 2003; 310: 830-835.
  9. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL: Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004; 109: 2221-2226.
  10. Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS: Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol 2005; 32: 839-844.
  11. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA: Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-227.
  12. Liu GZ, Liang B, Lau WB, Wang Y, Zhao J, Li R, Wang X, Yuan Y, Lopez BL, Christopher TA, Xiao C, Ma XL, Wang Y: High glucose/High Lipids impair vascular adiponectin function via inhibition of caveolin-1/ AdipoR1 signalsome formation. Free Radic Biol Med 2015; 89: 473-485.
  13. Forst T, Weber MM, Pfutzner A: Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res 2012; 2012: 635472.
  14. Koska J, Sands M, Burciu C, D’Souza KM, Raravikar K, Liu J, Truran S, Franco DA, Schwartz EA, Schwenke DC, D’Alessio D, Migrino RQ, Reaven PD: Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans. Diabetes 2015; 64: 2624-2635.
  15. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM: Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 2014; 9:e97554.
  16. Zhan Y, Sun HL, Chen H, Zhang H, Sun J, Zhang Z, Cai DH: Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Med Sci Monit 2012; 18:BR286-291.
  17. Schisano B, Harte AL, Lois K, Saravanan P, Al-Daghri N, Al-Attas O, Knudsen LB, McTernan PG, Ceriello A, Tripathi G: GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul Pept 2012; 174: 46-52.
  18. Sivertsen B, Holliday N, Madsen AN, Holst B: Functionally biased signalling properties of 7TM receptors-opportunities for drug development for the ghrelin receptor. Br J Pharmacol 2013; 170: 1349-1362.
  19. Mao Y, Tokudome T, Kishimoto I: Ghrelin and Blood Pressure Regulation. Curr Hypertens Rep 2016; 18: 15.
  20. Muccioli G, Lorenzi T, Lorenzi M, Ghe C, Arnoletti E, Raso GM, Castellucci M, Gualillo O, Meli R: Beyond the metabolic role of ghrelin: a new player in the regulation of reproductive function. Peptides 2011; 32: 2514-2521.
  21. Orlova EG, Shirshev SV, Loginova OA: Leptin and ghrelin regulate dendritic cell maturation and dendritic cell induction of regulatory T-cells. Dokl Biol Sci 2015; 462: 171-174.
  22. Tokudome T, Kishimoto I, Miyazato M, Kangawa K: Ghrelin and the cardiovascular system. Front Horm Res 2014; 43: 125-133.
  23. Wang L, Li G, Chen Q, Ke D: Octanoylated ghrelin attenuates angiogenesis induced by oxLDL in human coronary artery endothelial cells via the GHSR1a-mediated NF-kappaB pathway. Metabolism 2015; 64: 1262-1271.
  24. Wang L, Chen Q, Li G, Ke D: Ghrelin stimulates angiogenesis via GHSR1a-dependent MEK/ERK and PI3K/Akt signal pathways in rat cardiac microvascular endothelial cells. Peptides 2012; 33: 92-100.
  25. Deng B, Fang F, Yang T, Yu Z, Zhang B, Xie X: Ghrelin inhibits AngII -induced expression of TNF-alpha, IL-8, MCP-1 in human umbilical vein endothelial cells. Int J Clin Exp Med 2015; 8: 579-588.
    External Resources
  26. Shimada T, Furuta H, Doi A, Ariyasu H, Kawashima H, Wakasaki H, Nishi M, Sasaki H, Akamizu T: Des-acyl ghrelin protects microvascular endothelial cells from oxidative stress-induced apoptosis through sirtuin 1 signaling pathway. Metabolism 2014; 63: 469-474.
  27. Zhu J, Zheng C, Chen J, Luo J, Su B, Huang Y, Su W, Li Z, Cui T: Ghrelin protects human umbilical vein endothelial cells against high glucose-induced apoptosis via mTOR/P70S6K signaling pathway. Peptides 2014; 52: 23-28.
  28. Xiang Y, Li Q, Li M, Wang W, Cui C, Zhang J: Ghrelin inhibits AGEs-induced apoptosis in human endothelial cells involving ERK1/2 and PI3K/Akt pathways. Cell Biochem Funct 2011; 29: 149-155.
  29. Yin Y, Zhang W: The Role of Ghrelin in Senescence: A Mini-Review. Gerontology 2016; 62: 155-162.
  30. Veluthakal R, Kumar B, Mohammad G, Kowluru A, Kowluru RA: Tiam1-Rac1 Axis Promotes Activation of p38 MAP Kinase in the Development of Diabetic Retinopathy: Evidence for a Requisite Role for Protein Palmitoylation. Cell Physiol Biochem 2015; 36: 208-220.
  31. Ye M, Li D, Yang J, Xie J, Yu F, Ma Y, Zhu X, Zhao J, Lv Z: MicroRNA-130a Targets MAP3K12 to Modulate Diabetic Endothelial Progenitor Cell Function. Cell Physiol Biochem 2015; 36: 712-726.
  32. Inoue T, Inoguchi T, Sonoda N, Hendarto H, Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D, Takayanagi R: GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis 2015; 240: 250-259.
  33. Wu XM, Ou QY, Zhao W, Liu J, Zhang H: The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway. Exp Clin Endocrinol Diabetes 2014; 122: 608-614.
  34. Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, Joh T: Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009; 162: 1212-1219.
  35. Xu H, Li HL, Niu ZY, Li GZ, Cao J, Jiang YD: [Involvement of p38 MAPK pathway in GLP-1-induced inhibition of apoptosis in human umbilical vein endothelial cells]. Sheng Li Xue Bao 2012; 64: 444-448.
    External Resources
  36. Li P, Gan Y, Xu Y, Song L, Wang L, Ouyang B, Zhang C, Zhou Q: The inflammatory cytokine TNF-alpha promotes the premature senescence of rat nucleus pulposus cells via the PI3K/Akt signaling pathway. Sci Rep 2017; 7: 42938.
  37. Tan P, Wang YJ, Li S, Wang Y, He JY, Chen YY, Deng HQ, Huang W, Zhan JK, Liu YS: The PI3K/Akt/mTOR pathway regulates the replicative senescence of human VSMCs. Mol Cell Biochem 2016; 422: 1-10.
  38. Roediger J, Hessenkemper W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, Esmaeili M, Foller S, Petersen I, Grimm MO, Baniahmad A: Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer 2014; 13: 214.
  39. Zhao Q, Wang XY, Yu XX, Zhai YX, He X, Wu S, Shi YA: Expression of human telomerase reverse transcriptase mediates the senescence of mesenchymal stem cells through the PI3K/AKT signaling pathway. Int J Mol Med 2015; 36: 857-864.
  40. Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P, Ghigo E, Camussi G, Zanone MM: The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 2012; 55: 1058-1070.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 23, 2017
Accepted: October 14, 2017
Published online: December 07, 2017
Issue release date: Published online first (Issue-in-Progress)

Number of Print Pages: 14
Number of Figures: 7
Number of Tables: 0

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: https://www.karger.com/CPB


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.